• Caliway will give a company presentation on June 17 at the BIO International Convention 2025, the largest global event for the biotech industry.
• Caliway will, for the first time at an international conference, present preclinical data regarding a possible new use for CBL-514: preventing weight regain after GLP-1 therapy when used in combination.

NEW TAIPEI CITY, June 10, 2025 — Caliway Biopharmaceuticals (TWSE: 6919) today announced that it will participate in the 2025 BIO International Convention, scheduled from June 16 to 19 in Boston, U.S.A. April Yuan, Vice President of Caliway, will be giving a presentation on June 17 that highlights the company’s latest advancements in R&D and pipeline development.

The presentation will include the latest information on CBL-514, an innovative injectable drug candidate intended for localized fat reduction across large areas, as well as its development for several uses such as subcutaneous fat reduction, cellulite, and Dercum’s disease.

Caliway will also present, for the first time at an international conference, preclinical data on a potential new application: controlling weight rebound by combining it with GLP-1 receptor agonists.

As GLP-1 receptor agonists are becoming more widely used around the world, weight regain after stopping treatment has emerged as a major, yet unmet, clinical concern. According to published research, only 10% of patients can maintain their weight loss after discontinuing GLP-1 treatment.

Caliway’s preclinical data indicates that administering CBL-514 alongside GLP-1 considerably decreased body weight regain and fat replenishment after treatment was stopped—suggesting CBL-514 could help people maintain their weight loss after GLP-1 therapy.

CBL-514 functions by specifically targeting subcutaneous fat, the underlying cause, through the selective induction of adipocyte apoptosis. It may act as a complementary combination therapy to GLP-1s, combining systemic weight loss with precise body sculpting.

Caliway intends to submit a Phase 2 IND application to the U.S. FDA for this new application in Q4 2025.

“We see managing post-weight-loss weight regain as a market with significant unmet needs,” stated Vivian Ling, CEO of Caliway. “CBL-514 has the potential to be used as a complementary combination therapy alongside GLP-1 treatments, where GLP-1s promote weight loss, and CBL-514 reshapes the body and sustains results via localized fat reduction, improving the overall effectiveness and long-term benefits of the treatment.”

The BIO International Convention is the world’s largest and most influential biotechnology event, bringing together more than 20,000 professionals and 5,000 companies from over 80 countries. It serves as a global arena for investment, business development, and the exchange of innovation.

Caliway Presentation at BIO 2025:

• Date & Time: Tuesday, June 17, 2025 | 11:45 AM – 12:00 PM (EDT)
• Location: Room 154 | Boston Convention & Exhibition Center
• Speaker: April Yuan, VP, Caliway Biopharmaceuticals
• Session Info:

About CBL-514
CBL-514, a first-in-class small-molecule drug and 505(b)(1) drug developed by Caliway, is the first injectable lipolysis drug worldwide to use adipocyte apoptosis to reduce subcutaneous fat in specific areas without causing systemic side effects on the central nervous system, cardiovascular system, or respiratory system. As of May 2025, 10 clinical trials, including 520 subjects in total, have been finished, and all efficacy and safety goals were achieved.

Caliway is currently studying CBL-514 for several uses, including non-surgical fat reduction, moderate-to-severe cellulite, and managing weight regain through combination therapy using GLP-1-based treatments. CBL-514D, which contains the same active pharmaceutical ingredients (APIs) but in a different formulation, is being researched for additional uses, such as Dercum’s disease and others.

About Caliway Biopharmaceuticals
Caliway Biopharmaceuticals (Caliway) is a clinical-stage biopharmaceutical company focused on innovative drug discovery of new small-molecule therapeutics. Caliway, listed on the Taiwan Exchange (TWSE-6919), aspires to lead the pharmaceutical industry in aesthetic medicine and other disease treatments. More information is available at:

Disclaimer
This article and the information provided on this site include forward-looking statements. These statements involve a number of assumptions and are subject to inherent risks, uncertainties, and other factors that are beyond the company’s ability to control. These factors may cause actual results, performance, or achievements to differ significantly from the anticipated results, performance, or achievements expressed or suggested by these statements. The company is not obligated to update or revise the information on this site in a timely manner if circumstances change.

SOURCE Caliway Biopharmaceuticals

“`